Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice

Details

• Personal Author:
  Landgren O ; Morgan GJ
• Description:
  Since the mid-1990s, the multiple myeloma treatment landscape has evolved considerably, which has led to improved patient outcomes and prolonged survival. In addition to discovering new, targeted agents or treatment regimens, the identification and validation of biomarkers has the potential to further improve patient outcomes. The International Staging System relies on a number of biochemical parameters to stratify patients into risk categories. Other biologically relevant markers that are indicative of inherited genetic variation (e.g., single-nucleotide polymorphisms) or tumor-acquired genetic events (e.g., chromosomal translocations or mutations) have been studied for their prognostic potential. In patients with high-risk cytogenetics, plasma cells (PC) undergo genetic shifts over time, which may partially explain why high-risk patients relapse and are so difficult to treat. Although novel agents have improved treatment outcomes, identification of markers that will enable clinicians to determine which treatment is most appropriate for high-risk patients following initial diagnosis represents an exciting frontier in the clinical management of multiple myeloma. Biomarkers based on quantitating PCs or factors that are secreted from them (e.g., serum free light chain) may also help to risk-stratify patients with asymptomatic multiple myeloma. Eventually, identification of novel biomarkers may lead to the creation of personalized treatment regimens that are optimized to target clonal PCs that express a specific oncogenomic profile. Although the future is exciting, validation will be necessary before these biologic and molecular beacons can inform decision-making processes in a routine clinical setting. [Description provided by NIOSH]
• Subjects:
  Biomarkers Blood Decision Making Diagnosis Health Care Facilities Workforce And Services Immune System Neoplasms Occupational Health Risk Assessment Risk Factors Safety

  More +
• Keywords:
  Biochemical Indicators Biochemical Markers Biological Factors Blood Cells Bone Marrow Cancer Cell Alteration Clinical Diagnosis Clinical Pathology Clinical Techniques Decision Making Genetic Factors Genomics Hematopoietic System Immunoglobulins Medical Monitoring Medical Research Mutation Myeloid Tissue Oncogenesis Risk Factors Survival Rate Therapeutic Agents

  More +
• ISSN:
  1078-0432
• Document Type:
  Text
• Funding:
  Cooperative Agreement
• Genre:
  Journal Article
• Place as Subject:
  Maryland ; New York ; OSHA Region 2 ; OSHA Region 3
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  20
• Issue:
  4
• NIOSHTIC Number:
  nn:20050748
• Citation:
  Clin Cancer Res 2014 Feb; 20(4):804-813
• Contact Point Address:
  Ola Landgren, National Cancer Institute, NIH, Center for Cancer Research, Medical Oncology Branch, 9000 Rockville Pike, Building 10/Room 13N240, Bethesda, MD 20892
• Email:
  landgreo@mail.nih.gov
• Federal Fiscal Year:
  2014
• Performing Organization:
  Albert Einstein College of Medicine, Inc., Bronx, New York
• Peer Reviewed:
  True
• Start Date:
  20170701
• Source Full Name:
  Clinical Cancer Research
• End Date:
  20200630
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:b1f05db9cd595e906bd80c87c2713a9a796ba238cf7c30ec67b535a7ed43d1c9b856134a0405a0e3e496f39a50b17e8db6c10bb7a9f518efa88c958a5e9264df
• Download URL:
  https://stacks.cdc.gov/view/cdc/210972/cdc_210972_DS1.pdf
• File Type:
  [PDF - 440.31 KB ]